India's trade curbs and PLI push to boost domestic pharma against China: Arun Patel

The Indian pharmaceutical companies are profiting from the Union government’s minimum import-price measures, anti-dumping action and PLI-led (production linked incentive) capacity creation which are

To access the full article, please log in or subscribe.